204 related articles for article (PubMed ID: 36139433)
1. The Role of Neutrophils in Oncolytic Orf Virus-Mediated Cancer Immunotherapy.
Minott JA; van Vloten JP; Chan L; Mehrani Y; Bridle BW; Karimi K
Cells; 2022 Sep; 11(18):. PubMed ID: 36139433
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer.
van Vloten JP; Matuszewska K; Minow MAA; Minott JA; Santry LA; Pereira M; Stegelmeier AA; McAusland TM; Klafuric EM; Karimi K; Colasanti J; McFadden DG; Petrik JJ; Bridle BW; Wootton SK
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296558
[TBL] [Abstract][Full Text] [Related]
3. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
[TBL] [Abstract][Full Text] [Related]
4. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow.
Breitbach CJ; Paterson JM; Lemay CG; Falls TJ; McGuire A; Parato KA; Stojdl DF; Daneshmand M; Speth K; Kirn D; McCart JA; Atkins H; Bell JC
Mol Ther; 2007 Sep; 15(9):1686-93. PubMed ID: 17579581
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
6. Integrating oncolytic viruses in combination cancer immunotherapy.
Bommareddy PK; Shettigar M; Kaufman HL
Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic vaccinia virus and cancer immunotherapy.
Xu L; Sun H; Lemoine NR; Xuan Y; Wang P
Front Immunol; 2023; 14():1324744. PubMed ID: 38283361
[TBL] [Abstract][Full Text] [Related]
8. Transient inhibition of neutrophil functions enhances the antitumor effect of intravenously delivered oncolytic vaccinia virus.
Zhou D; Xu W; Ding X; Guo H; Wang J; Zhao G; Zhang C; Zhang Z; Wang Z; Wang P; Lu L; Yuan M
Cancer Sci; 2024 Apr; 115(4):1129-1140. PubMed ID: 38351514
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulation in Oncolytic Measles Virotherapy.
Dietz L; Engeland CE
Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
[TBL] [Abstract][Full Text] [Related]
10. Virus specific tolerance enhanced efficacy of cancer immuno-virotherapy.
Sobhanimonfared F; Bamdad T; Sadigh ZA; Choobin H
Microb Pathog; 2020 Mar; 140():103957. PubMed ID: 31891795
[TBL] [Abstract][Full Text] [Related]
11. Virotherapy induces massive infiltration of neutrophils in a subset of tumors defined by a strong endogenous interferon response activity.
Fu X; Tao L; Rivera A; Xu H; Zhang X
Cancer Gene Ther; 2011 Nov; 18(11):785-94. PubMed ID: 21869820
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the Impact of Oncolytic Vesicular Stomatitis Virus on the Trafficking, Phenotype, and Antigen Presentation Potential of Neutrophils and Their Ability to Acquire a Non-Structural Viral Protein.
Stegelmeier AA; Chan L; Mehrani Y; Petrik JJ; Wootton SK; Bridle B; Karimi K
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882969
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
Deng L; Fan J; Guo M; Huang B
Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
[TBL] [Abstract][Full Text] [Related]
15. Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy.
Zhang B; Cheng P
Mol Cancer; 2020 Nov; 19(1):158. PubMed ID: 33172438
[TBL] [Abstract][Full Text] [Related]
16. The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.
Rommelfanger DM; Compte M; Grau MC; Diaz RM; Ilett E; Alvarez-Vallina L; Thompson JM; Kottke TJ; Melcher A; Vile RG
Mol Ther; 2013 Feb; 21(2):348-57. PubMed ID: 23011032
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
[TBL] [Abstract][Full Text] [Related]
18. Identification of in vitro and in vivo oncolytic effect in colorectal cancer cells by Orf virus strain NA1/11.
Chen D; Wang R; Long M; Li W; Xiao B; Deng H; Weng K; Gong D; Liu F; Luo S; Hao W
Oncol Rep; 2021 Feb; 45(2):535-546. PubMed ID: 33416161
[TBL] [Abstract][Full Text] [Related]
19. Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy.
Ghonime MG; Saini U; Kelly MC; Roth JC; Wang PY; Chen CY; Miller K; Hernandez-Aguirre I; Kim Y; Mo X; Stanek JR; Cripe T; Mardis E; Cassady KA
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599026
[TBL] [Abstract][Full Text] [Related]
20. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
